BioAlliance Pharma SA , the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the grant of its main patent on the Lauriad technology in Europe.
The patent describes and protects a muco-adhesive tablet for various applications in the field of opportunistic infections associated with AIDS and cancer. It has been validated in the main European countries and the opposition period has now expired.
"The grant of this patent acknowledges the true innovation behind the Lauriad muco-adhesive technology", stated Dominique Costantini, president and CEO of BioAlliance Pharma. "It reinforces our positioning in the target markets for the Lauriad technology: oropharyngeal candidiasis, labial herpes and chronic pain".
Given BioAlliance Pharma's commitment to the development and commercialization of innovative products, intellectual property (IP) is at the heart of the company's business activity. The company is developing a pro-active IP strategy that is tightly coupled to its R&D projects.
BioAlliance Pharma's patent portfolio now encompasses 25 published patent families (comprising 196 patent applications and granted patents) covering innovative technologies or products in the fields of opportunistic infections, cancer and AIDS. More than half the portfolio is made up of granted patents.
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg.